New molecular insights into osteosarcoma targeted therapy

Current Opinion in Oncology

Volumn 25, Issue 4, 2013, Pages 398-406

  Yang, Jilong ^a   Zhang, Wei ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

genetic aberration; microRNA; molecular target; osteosarcoma; pathogenesis

Indexed keywords

BECLIN 1; BEVACIZUMAB; CALPAIN 2; CASPASE 3; DOXORUBICIN; EZRIN; FRUCTOSE BISPHOSPHATE; FRUCTOSE BISPHOSPHATE ALDOLASE; HEAT SHOCK PROTEIN 70; HIGH MOBILITY GROUP B1 PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTEGRIN; INTERLEUKIN 11; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN; MATRIX METALLOPROTEINASE; MICRORNA; NOTCH RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; POLO LIKE KINASE 1; PROTEIN MDM2; PROTEIN P53; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; STATIN (PROTEIN); TRANSCRIPTION FACTOR NFAT; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CELL INVASION; CELL LINEAGE; CELL MIGRATION; CELL POPULATION; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; CHROMOSOME ABERRATION; DRUG SENSITIVITY; GENE AMPLIFICATION; GENE MUTATION; HUMAN; INTRACELLULAR SIGNALING; KARYOTYPE; METASTASIS; NONHUMAN; ONCOGENE C KIT; ONCOGENE C MYC; ONCOGENE SRC; OSTEOCLAST; OSTEOSARCOMA; OSTEOSARCOMA CELL; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTO ONCOGENE; RADIOSENSITIVITY; REVIEW; TUMOR GROWTH; WNT SIGNALING PATHWAY;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; OSTEOSARCOMA;

EID: 84879889989     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3283622c1b     Document Type: Review

References (53)

1. Ottaviani G, Jaffe N, Delling G, et al. The epidemiology of osteosarcoma. Cancer Treat Res 2009; 152:3-13.
2. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in highgrade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20:776-790. (Pubitemid 34111386)
3. Broadhead ML, Clark JC, Myers DE, et al. The molecular pathogenesis of osteosarcoma: a review. Sarcoma 2011; 2011:959248.
4. Yang J, Cogdell D, Yang D, et al. Deletion of the wwox gene and frequent loss of its protein expression in human osteosarcoma. Cancer Lett 2010; 291:31-38.
5. Yang J, Yang D, Sun Y, et al. Genetic amplification of the vascular endothelial growth factor (vegf) pathway genes, including vegfa, in human osteosarcoma. Cancer 2011; 117:4925-4938.
6. Yang J, Yang D, Cogdell D, et al. Apex1 gene amplification and its protein overexpression in osteosarcoma: correlation with recurrence, metastasis, and survival. Technol Cancer Res Treat 2010; 9:161-169.
7. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23:1011-1027. (Pubitemid 46202320)
8. Wan X, Mendoza A, Khanna C, Helman LJ. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 2005; 65:2406-2411. (Pubitemid 40490152)
9. Dieudonne FX, Marion A, Hay E, et al. High wnt signaling represses the proapoptotic proteoglycan syndecan-2 in osteosarcoma cells. Cancer Res 2010; 70:5399-5408.
10. Cai Y, Mohseny AB, Karperien M, et al. Inactive wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol 2010; 220:24-33.
11. Maire G, Yoshimoto M, Chilton-MacNeill S, et al. Recurrent recql4 imbalance and increased gene expression levels are associated with structural chromosomal instability in sporadic osteosarcoma. Neoplasia 2009; 11: 260-268.
12. Shimizu T, Ishikawa T, Sugihara E, et al. C-myc overexpression with loss of ink4a/arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis. Oncogene 2010; 29:5687-5699.
13. Lenos K, Grawenda AM, Lodder K, et al. Alternate splicing of the p53 inhibitor hdmx offers a superior prognostic biomarker than p53 mutation in human cancer. Cancer research 2012; 72:4074-4084.
14. Wan X, Kim SY, Guenther LM, et al. Beta4 integrin promotes osteosarcoma metastasis and interacts with ezrin. Oncogene 2009; 28:3401-3411.
15. Brambilla D, Zamboni S, Federici C, et al. P-glycoprotein binds to ezrin at amino acid residues 149-242 in the ferm domain and plays a key role in the multidrug resistance of human osteosarcoma. Int J Cancer 2012; 130:2824-2834.
16. Fromigue O, Hamidouche Z, Vaudin P, et al. Cyr61 downregulation reduces osteosarcoma cell invasion, migration, and metastasis. J Bone Miner Res 2011; 26:1533-1542.
17. Zhang P, Yang Y, Nolo R, et al. Regulation of notch signaling by reciprocal inhibition of hes1 and deltex 1 and its role in osteosarcoma invasiveness. Oncogene 2010; 29:2916-2926.
18. Li Y, Zhang J, Ma D, et al. Curcumin inhibits proliferation and invasion of osteosarcoma cells through inactivation of notch-1 signaling. FEBS J 2012; 279:2247-2259.
19. Chen X, Yang TT, Zhou Y, et al. Proteomic profiling of osteosarcoma cells identifies aldoa and sult1a3 as negative survival markers of human osteosarcoma. Mol Carcinog 2012. 10.1002/mc.21957. [Epub ahead of print].
20. Ammirante M, Rosati A, Arra C, et al. Ikk{gamma} protein is a target of bag3 regulatory activity in human tumor growth. Proc Natl Acad Sci U S A 2010; 107:7497-7502.
21. Xie XK, Yang DS, Ye ZM, Tao HM. Recombinant antisense c-myc adenovirus increase in vitro sensitivity of osteosarcoma mg-63 cells to cisplatin. Cancer Invest 2006; 24:1-8.
22. Akiyama T, Dass CR, Choong PF. Bim-targeted cancer therapy: a link between drug action and underlying molecular changes. Mol Cancer Ther 2009; 8:3173-3180.
23. Gillings AS, Balmanno K, Wiggins CM, et al. Apoptosis and autophagy: Bim as a mediator of tumour cell death in response to oncogene-targeted therapeutics. FEBS J 2009; 276:6050-6062.
24. Yamaguchi U, Honda K, Satow R, et al. Functional genome screen for therapeutic targets of osteosarcoma. Cancer Sci 2009; 100:2268-2274.
25. Liang D, Yang M, Guo B, et al. Hif-1alpha induced by beta-elemene protects human osteosarcoma cells from undergoing apoptosis. J Cancer Res Clin Oncol 2012; 138:1865-1877.
26. Yang C, Ji D, Weinstein EJ, et al. The kinase mirk is a potential therapeutic target in osteosarcoma. Carcinogenesis 2010; 31:552-558.
27. Wang ZX, Yang JS, Pan X, et al. Functional and biological analysis of bcl-xl expression in human osteosarcoma. Bone 2010; 47:445-454.
28. Sueyoshi T, Jono H, Shinriki S, et al. Therapeutic approaches targeting midkine suppress tumor growth and lung metastasis in osteosarcoma. Cancer Lett 2012; 316:23-30.
29. Rouleau C, Sancho J, Campos-Rivera J, Teicher BA. Endosialin expression in side populations in human sarcomacell lines.Oncology Lett 2012; 3:325-329.
30. Ichikawa J, Cole HA, Magnussen RA, et al. Thrombin induces osteosarcoma growth, a function inhibited by low molecular weight heparin in vitro and in vivo: Procoagulant nature of osteosarcoma. Cancer 2012; 118:2494-2506.
31. Hassan SE, Bekarev M, Kim MY, et al. Cell surface receptor expression patterns in osteosarcoma. Cancer 2012; 118:740-749.
32. Huang J, Ni J, Liu K, et al. Hmgb1 promotes drug resistance in osteosarcoma. Cancer Res 2012; 72:230-238.
33. Wang YH, Wang ZX, Qiu Y, et al. Lentivirus-mediated rnai knockdown of insulin-like growth factor-1 receptor inhibits growth, reduces invasion, and enhances radiosensitivity in human osteosarcoma cells. Mol Cell Biochem 2009; 327:257-266.
34. Avnet S, Sciacca L, Salerno M, et al. Insulin receptor isoform a and insulin-like growth factor ii as additional treatment targets in human osteosarcoma. Cancer Res 2009; 69:2443-2452.
35. Ebb D, Meyers P, Grier H, et al. Phase ii trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group. J Clin Oncol 2012; 30:2545-2551.
36. Lu BJ, Wang YQ, Wei XJ, et al. Expression of wnt-5a and ror2 correlates with disease severity in osteosarcoma. Mol Med Rep 2012; 5:1033-1036.
37. Morioka K, Tanikawa C, Ochi K, et al. Orphan receptor tyrosine kinase ror2 as a potential therapeutic target for osteosarcoma. Cancer Sci 2009; 100:1227-1233.
38. Enomoto M, Hayakawa S, Itsukushima S, et al. Autonomous regulation of osteosarcoma cell invasiveness by wnt5a/ror2 signaling. Oncogene 2009; 28:3197-3208.
39. Akiyama T, Dass CR, Choong PF. Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway. Mol Cancer Ther 2008; 7:3461-3469.
40. McCleese JK, Bear MD, Fossey SL, et al. The novel hsp90 inhibitor sta-1474 exhibits biologic activity against osteosarcoma cell lines. Int J Cancer 2009; 125:2792-2801.
41. Liontos M, Niforou K, Velimezi G, et al. Modulation of the e2f1-driven cancer cell fate by the DNA damage response machinery and potential novel e2f1 targets in osteosarcomas. Am J Pathol 2009; 175:376-391.
42. Wang YC, Zheng LH, Ma BA, et al. Clinical value of signal transducers and activators of transcription 3 (stat3) gene expression in human osteosarcoma. Acta Histochemica 2011; 113:402-408.
43. Chen Z, Huang C, Yang YL, et al. Inhibition of the stat3 signaling pathway is involved in the antitumor activity of cepharanthine in saos2 cells. Acta pharmacologica Sinica 2012; 33:101-108.
44. Fujii M. Exploration of a new drug that targets yap. J Biochem 2012; 152:209-211.
45. Bao Y, Nakagawa K, Yang Z, et al. A cell-based assay to screen stimulators of the hippo pathway reveals the inhibitory effect of dobutamine on the yap-dependent gene transcription. J Biochemi 2011; 150:199-208.
46. Salas S, Jezequel P, Campion L, et al. Molecular characterization of the response to chemotherapy in conventional osteosarcomas: predictive value of hsd17b10 and ifitm2. Int J Cancer 2009; 125:851-860.
47. Spina A, Sorvillo L, Di Maiolo F, et al. Inorganic phosphate enhances sensitivity of human osteosarcoma u2os cells to doxorubicin via a p53- dependent pathway. J Cell Physiol 2013; 228:198-206.
48. Kobayashi E, Hornicek FJ, Duan Z, et al. MicroRNA involvement in osteosarcoma. Sarcoma 2012; 2012:359739.
49. Jones KB, Salah Z, Del Mare S, et al. Mirna signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res 2012; 72:1865-1877.
50. Liu LH, Li H, Li JP, et al. Mir-125b suppresses the proliferation and migration of osteosarcoma cells through down-regulation of stat3. Biochem Biophys Res Commun 2011; 416:31-38.
51. Osaki M, Takeshita F, Sugimoto Y, et al. Microrna-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression. Mol Ther 2011; 19:1123-1130.
52. Cai CK, Zhao GY, Tian LY, et al. Mir-15a and mir-16-1 downregulate ccnd1 and induce apoptosis and cell cycle arrest in osteosarcoma. Oncol Rep 2012; 28:1764-1770.
53. Song B, Wang Y, Titmus MA, et al. Molecular mechanism of chemoresistance by mir-215 in osteosarcoma and colon cancer cells. Mol Cancer 2010; 9:96. Fund